Abstract
Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 101-106 |
| Number of pages | 6 |
| Journal | Annals of Clinical and Laboratory Science |
| Volume | 19 |
| Issue number | 2 |
| State | Published - Jan 1 1989 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)
- Clinical Biochemistry
Cite this
}
Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease. / Mark, Margery; Sage, Jacob.
In: Annals of Clinical and Laboratory Science, Vol. 19, No. 2, 01.01.1989, p. 101-106.Research output: Contribution to journal › Article
TY - JOUR
T1 - Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease
AU - Mark, Margery
AU - Sage, Jacob
PY - 1989/1/1
Y1 - 1989/1/1
N2 - Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.
AB - Twelve of 23 patients with Parkinson's disease and motor fluctuations who entered a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR-4) with standard Sinemet (SS) continued into open label follow-up on a combination of CR-4 and SS (C/S); the rest continued on CR-4 alone. Significant improvement on C/S compared with CR-4 was noted for shorter duration and reduced disability of dyskinesias, and more hours 'on' without dyskinesias (all p < 0.05). Total number of hours 'off' was improved on C/S over SS (p < 0.01). Sinemet CR-4 proved to be better than C/S for sleep disturbance (p < 0.05). Although the total number of tablets and doses per day of CR-4 was reduced during the C/S period, total levodopa dosage per day was not significantly changed from either of the previous periods. The C/S therapy for advanced parkinsonism can be more efficacious for fluctuators than either CR-4 or SS alone.
UR - http://www.scopus.com/inward/record.url?scp=0024536814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024536814&partnerID=8YFLogxK
M3 - Article
C2 - 2665626
AN - SCOPUS:0024536814
VL - 19
SP - 101
EP - 106
JO - Annals of Clinical and Laboratory Science
JF - Annals of Clinical and Laboratory Science
SN - 0091-7370
IS - 2
ER -